What does the research say about BPC-157?
What it was studied for, where the human evidence stands, and why FDA hasn't approved it.
For curious people trying to make sense of peptide headlines: plain-language explanations, clearly labeled evidence, and links to the original sources.
If you have seen a striking claim about a peptide and wondered what the study really says, start here. We explain what was investigated, who or what was studied, and what remains uncertain. A human study, an animal experiment, a laboratory result, a review, and a company claim get different labels. You can follow the sources and see how an agency announcement differs from a research finding. Bring your questions; leave with a clearer way to read the evidence.
What it was studied for, where the human evidence stands, and why FDA hasn't approved it.
The committee backed six of seven peptides. None of it is final.
A proposal about one compounding pathway, not every GLP-1 product.
We color-code every claim by where it came from, so you can tell a lab finding from a human trial at a glance.
Research done in people, such as clinical trials and observational studies. The closest evidence to real-world use, but size, design, and who was studied still matter.
Research in animals such as mice or rats. Useful for early signals. Results often fail to carry over to people.
Cells or tissue in a dish (in vitro). Shows a possible mechanism, not an effect in a living body.
A summary of other studies. Only as strong as the studies it covers and how they were chosen.
A press release, investor update, or marketing claim. Not peer reviewed. Reported as a claim, not a finding.
An agency notice, rule, briefing or meeting record. It tells you what a regulator did or said, not what research found, so it gets a neutral label with no evidence color. We name the agency, link the notice, and say whether a change is proposed or enacted.